Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic Cooperative Oncology Group study

Oncology

Volumn 56, Issue 3, 1999, Pages 198-201

  Bafaloukos, Dimitrios ^a   Aravantinos, G ^b   Samonis, G ^c   Katsifis, G ^a   Bakoyiannis, C ^a   Skarlos, D ^b   Kosmidis, P ^a  

^a METAXA CANCER HOSPITAL   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Carboplatin; Chemotherapy; Endometrial carcinoma; Hormonotherapy; Medroxyprogesterone acetate

Indexed keywords

CARBOPLATIN; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING; WEIGHT GAIN;

EID: 0032903136     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011965     Document Type: Article

References (24)

1. Moore TD, Phillips PH, Nerenstone SR, et al: Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol 1991;9:1071-1088.
2. Muss HB: Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994;21:107-119.
3. Thigpen T, Blessing J, Homesley H, et al: Phase III trial of doxorubicin+/-cisplatin in advanced or recurrent endometrial carcinoma: A gynecologic oncology group (GOG) study. Proc Am Soc Clin Oncol 1993;12:261.
4. Long HJ, Pfeifle DM, Wieand HS, et al: Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988;80: 276-278.
5. Green JB III, Green S, Alberts DS, et al: Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990;75:696-700.
6. Burke TW Munkarah A, Kavanagh J, et al: Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993;51:397-400.
7. DeVita VT, Wasserman TH, Young RC, et al: Perspectives on research in gynecologic oncology: Treatment protocols. Cancer 1976;38:509-525.
8. Cadman E, Heimer R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration - Explanation for drug synergism. Science 1979;205:1135.
9. Benz C, Cadman E: Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Rev 1981;1:994.
10. Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960-969.
11. Moore TD, Phillips PH, Nerenstone SR, et al: Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future prospects. J Clin Oncol 1991;9:1071-1088.
12. Ayoub J, Audet-Lapointe P, Methot Y, et al: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-337.
13. Fanning J, Piver MS: Serial CA 125 levels during chemotherapy for metastatic or recurrent endometrial cancer. Obstet Gynecol 1991;77: 278-280.
14. Fuller AF Jr, Krane IM, Budzik GP, et al: Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol 1985;22:135-148.
15. WHO: WHO Handbook for reporting results of cancer treatment. Geneva, WHO Offset Publication No 48, 1979.
16. Hayward JL, Rubens RD, Carbone PP, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-298.
17. Cohen CJ, Bruckner HW, Deppe G, et al: Multidrug treatment of advanced and recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Obstet Gynecol 1984;63:719-726.
18. Thigpen T, Blessing J, DiSaia P: Treatment of advanced or recurrent endometrial carcinoma with medroxyprogesterone acetate (MPA): A Gynecologic Oncology Group Study. Gynecol Oncol 1985;20:250.
19. Pinelli DM, Fiorica JV, Roberts WS, et al: Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma. A phase II study. Gynecol Oncol 1996; 60:462-467.
20. Bonte J, Decoster J, Ide P: Hormonoprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate. Gynecol Oncol 1978;6:60.
21. Fujimoto J, Tamaya T, Okada H: Response indicators of chemoendocrine therapy for uterine cancer by colony-forming assay (ABST). Proc Annu Meet Jpn Cancer Assoc 1986;45: 365.
22. Deppe U, Jacobs AJ, Brickner H, et al: Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate. Am J Obstet Gynecol 1981;140:313.
23. Horton J, Elson P, Gordon P: Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Cancer 1982;49:2441.
24. Ayoub J, Audet-LaPoint P, Metrot Y: Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-337.